NCT00561392 Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease Status COMPLETED Phase PHASE4
NCT00555204 Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease Status TERMINATED Phase PHASE2
NCT00551772 A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers. Status COMPLETED Phase PHASE1
NCT00550420 Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers Status TERMINATED Phase PHASE3
NCT00549601 Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease Status COMPLETED Phase PHASE4
NCT00544856 Effects of a Complex Cognitive Training in Mild Cognitive Impairment and Mild Alzheimer's Disease Status COMPLETED Phase NA
NCT00531804 A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease. Status COMPLETED Phase PHASE1
NCT00523666 Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®) Status UNKNOWN Phase PHASE4
NCT00499200 Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy Status COMPLETED Phase PHASE1
NCT00495820 Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study Status COMPLETED Phase PHASE4
NCT00495417 Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease Status COMPLETED Phase PHASE1
NCT00490568 Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers Status TERMINATED Phase PHASE3
NCT00483028 A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI Status COMPLETED Phase NA
NCT00478491 fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease Status COMPLETED Phase N/A
NCT00478205 Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease Status COMPLETED Phase PHASE3